alipogene tiparvovec
AXP000248.1 · Viral vector gene therapy
- Platform
- AAV1 vector
- Targets
- LPL
- Originator
- Amsterdam Molecular Therapeutics
- Sponsor
- uniQure
Names
Virus
- Role
- In vivo gene transfer
- Family
- Parvoviridae
- Virus
- adeno-associated virus 1
- Strain
- AAV1
- Replication
- non replicating
- Transgenes
- LPL (S447X variant)
- Route
- intramuscular
- Source
- evidence
Approvals
| Agency | Region | Date | Status | Brand | Indication | Source |
|---|---|---|---|---|---|---|
| EMA | EU | 2012-10-25 | withdrawn | Glybera | Familial lipoprotein lipase deficiency with severe or multiple pancreatitis attacks despite dietary fat restriction; authorisation expired 2017-10-28 | source |
Clinical trials (5)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT02904772 | Alipogene Tiparvovec for the Treatment of LPLD Patients | Withdrawn | Phase 2 | 2016-10 | 2020-06 | 0 | LPL Deficiency |
| NCT03293810 | Glybera Registry, Lipoprotein Lipase Deficient (LPLD) Patients | Completed | 2014-06-27 | 2023-06 | 16 | Familial Hyperchylomicronemia; Familial Hyperlipoproteinemia Type 1; Lipoprotein Lipase Deficiency | |
| NCT01447901 | Duration of Effect of Alipogene Tiparvovec Treatment, Which Was Administered in Other Studies | Terminated | 2011-09 | 2012-09 | 19 | Hyperlipoproteinemia Type I | |
| NCT00891306 | Efficacy and Safety of Human Lipoprotein Lipase (LPL)[S447X] Expressed by an Adeno-Associated Viral Vector in LPL-deficient Subjects | Completed | Phase 2/3 | 2009-02 | 2010-08 | 5 | Familial Lipoprotein Lipase Deficiency |
| NCT01109498 | Safety and Efficacy in LPL-Deficient Subjects of AMT-011, an Adeno-Associated Viral Vector Expressing Human Lipoprotein Lipase [S447X] | Unknown | Phase 2/3 | 2007-08 | 2013-06 | 14 | Familial Lipoprotein Lipase Deficiency |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 29641318 | Gene Therapy in Lipoprotein Lipase Deficiency: Case Report on the First Patient Treated with Alipogene Tiparvovec Under Daily Practice Conditions. | Human gene therapy | 2018 | name in title: alipogene tiparvovec |
| PMID 24299335 | Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPL(S447X)) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy. | Human gene therapy | 2014 | name in title: alipogene tiparvovec |
| PMID 22717743 | Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. | Gene therapy | 2013 | cited by trial NCT01109498 |
| PMID 22438229 | Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients. | The Journal of clinical endocrinology and metabolism | 2012 | cited by trial NCT00891306 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40928580 | Making Advanced Therapies Affordable and Accessible: Two Strategic Approaches. | Developing world bioethics | 2026 | name in abstract: Glybera |
| PMID 37597209 | Preclinical Development and Characterization of Novel Adeno-Associated Viral Vectors for the Treatment of Lipoprotein Lipase Deficiency. | Human gene therapy | 2023 | name in abstract: Glybera |
| PMID 38462459 | Viral Vectors in Gene Replacement Therapy. | Biochemistry. Biokhimiia | 2023 | name in abstract: Glybera |
| PMID 36204465 | Genetic engineering of baculovirus-insect cell system to improve protein production. | Frontiers in bioengineering and biotechnology | 2022 | name in abstract: Glybera |
| PMID 33594520 | Evolving AAV-delivered therapeutics towards ultimate cures. | Journal of molecular medicine (Berlin, Germany) | 2021 | name in abstract: Glybera |
| PMID 34790341 | An overview of health technology assessments of gene therapies with the focus on cost-effectiveness models. | Journal of market access & health policy | 2021 | name in abstract: Glybera |
| PMID 31617173 | Engineering HSV-1 Vectors for Gene Therapy. | Methods in molecular biology (Clifton, N.J.) | 2020 | name in abstract: alipogene tiparvovec |
| PMID 31738617 | Recent developments in pharmacotherapy for hypertriglyceridemia: what's the current state of the art? | Expert opinion on pharmacotherapy | 2020 | name in abstract: alipogene tiparvovec |
| PMID 31836454 | Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery. | Pharmacology & therapeutics | 2020 | name in abstract: Glybera |
| PMID 31982038 | Muscle-Directed Delivery of an AAV1 Vector Leads to Capsid-Specific T Cell Exhaustion in Nonhuman Primates and Humans. | Molecular therapy : the journal of the American Society of Gene Therapy | 2020 | name in abstract: Glybera |
| PMID 30333169 | High-Resolution Structural Characterization of a New Adeno-associated Virus Serotype 5 Antibody Epitope toward Engineering Antibody-Resistant Recombinant Gene Delivery Vectors. | Journal of virology | 2019 | name in abstract: Glybera |
| PMID 30702996 | Lipid-Lowering Agents. | Circulation research | 2019 | name in abstract: alipogene tiparvovec |
| PMID 30968714 | The Landscape of Cellular and Gene Therapy Products: Authorization, Discontinuations, and Cost. | Human gene therapy. Clinical development | 2019 | name in abstract: alipogene tiparvovec |
| PMID 31261383 | Next-generation AAV vectors-do not judge a virus (only) by its cover. | Human molecular genetics | 2019 | name in abstract: Glybera |
| PMID 31283441 | Recombinant Adeno-Associated Virus Gene Therapy in Light of Luxturna (and Zolgensma and Glybera): Where Are We, and How Did We Get Here? | Annual review of virology | 2019 | name in title: Glybera |
| PMID 29351106 | The role of patient registries for rare genetic lipid disorders. | Current opinion in lipidology | 2018 | name in abstract: alipogene tiparvovec |
| PMID 29491255 | A Novel Approach to the Treatment of Plasma Protein Deficiency: Ex Vivo-Manipulated Adipocytes for Sustained Secretion of Therapeutic Proteins. | Chemical & pharmaceutical bulletin | 2018 | name in abstract: Glybera |
| PMID 29723270 | Creating an arsenal of Adeno-associated virus (AAV) gene delivery stealth vehicles. | PLoS pathogens | 2018 | name in abstract: Glybera |
| PMID 29842811 | Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome. | Expert review of clinical pharmacology | 2018 | name in abstract: alipogene tiparvovec |
| PMID 30298129 | Recent Progress in European Advanced Therapy Medicinal Products and Beyond. | Frontiers in bioengineering and biotechnology | 2018 | name in abstract: Glybera |
| PMID 30403015 | Triglyceride-Rich Lipoproteins and Novel Targets for Anti-atherosclerotic Therapy. | Korean circulation journal | 2018 | name in abstract: alipogene tiparvovec |
| PMID 31282760 | The rapidly evolving state of gene therapy. | FASEB journal : official publication of the Federation of American Societies for Experimental Biology | 2018 | name in abstract: Glybera |
| PMID 27548881 | The potential of toxin-based drug delivery systems for enhanced nucleic acid therapeutic delivery. | Expert opinion on drug delivery | 2017 | name in abstract: alipogene tiparvovec |
| PMID 27762892 | Evaluating the Past, Present, and Future of Regenerative Medicine: A Global View. | Tissue engineering. Part B, Reviews | 2017 | name in abstract: Glybera |
| PMID 27984852 | Biochemical Analysis of the Lipoprotein Lipase Truncation Variant, LPLS447X, Reveals Increased Lipoprotein Uptake. | Biochemistry | 2017 | name in abstract: alipogene tiparvovec |
| PMID 28284702 | The role of registries in rare genetic lipid disorders: Review and introduction of the first global registry in lipoprotein lipase deficiency. | Atherosclerosis | 2017 | name in abstract: alipogene tiparvovec |
| PMID 28351174 | Manufacturing Clinical Grade Recombinant Adeno-Associated Virus Using Invertebrate Cell Lines. | Human gene therapy | 2017 | name in abstract: Glybera |
| PMID 28560211 | Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe. | Frontiers in medicine | 2017 | name in abstract: Glybera |
| PMID 28591128 | After Glybera's withdrawal, what's next for gene therapy? | Nature biotechnology | 2017 | name in title: Glybera |
| PMID 28749065 | Concise Review: The High Cost of High Tech Medicine: Planning Ahead for Market Access. | Stem cells translational medicine | 2017 | name in abstract: Glybera |
| PMID 29101575 | Current and Future Treatments for Lysosomal Storage Disorders. | Current treatment options in neurology | 2017 | name in abstract: Glybera |
| PMID 29259533 | Regulatory Considerations for Gene Therapy Products in the US, EU, and Japan. | The Yale journal of biology and medicine | 2017 | name in abstract: alipogene tiparvovec |
| PMID 26519140 | Progress and challenges in viral vector manufacturing. | Human molecular genetics | 2016 | name in abstract: Glybera |
| PMID 27148842 | The Future of Hemophilia Treatment: Longer-Acting Factor Concentrates versus Gene Therapy. | Seminars in thrombosis and hemostasis | 2016 | name in abstract: Glybera |
| PMID 27412455 | Long-Term Retrospective Analysis of Gene Therapy with Alipogene Tiparvovec and Its Effect on Lipoprotein Lipase Deficiency-Induced Pancreatitis. | Human gene therapy | 2016 | name in title: alipogene tiparvovec |
| PMID 27448786 | Human gene therapy: novel approaches to improve the current gene delivery systems. | Discovery medicine | 2016 | name in abstract: Glybera |
| PMID 25559420 | Alipogene tiparvovec: a review of its use in adults with familial lipoprotein lipase deficiency. | Drugs | 2015 | name in title: alipogene tiparvovec |
| PMID 25633169 | Glybera's second act: the curtain rises on the high cost of therapy. | Molecular therapy : the journal of the American Society of Gene Therapy | 2015 | name in title: Glybera |
| PMID 25748892 | $1-million price tag set for Glybera gene therapy. | Nature biotechnology | 2015 | name in title: Glybera |
| PMID 25800821 | The baculovirus expression vector system: A commercial manufacturing platform for viral vaccines and gene therapy vectors. | Biotechnology journal | 2015 | name in abstract: Glybera |
| PMID 26052534 | Re-examination of regulatory opinions in Europe: possible contribution for the approval of the first gene therapy product Glybera. | Molecular therapy. Methods & clinical development | 2015 | name in title: Glybera |
| PMID 26236188 | Gene therapy and peripheral nerve repair: a perspective. | Frontiers in molecular neuroscience | 2015 | name in abstract: Glybera |
| PMID 26780002 | Novel therapeutics in hypertriglyceridemia. | Current opinion in lipidology | 2015 | name in abstract: alipogene tiparvovec |
| PMID 26780008 | Gene-based therapies in lipidology: current status and future challenges. | Current opinion in lipidology | 2015 | name in abstract: Glybera |
| PMID 24308784 | Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera®). | Expert review of clinical pharmacology | 2014 | name in title: alipogene tiparvovec |
| PMID 24624131 | Immune Responses to AAV-Vectors, the Glybera Example from Bench to Bedside. | Frontiers in immunology | 2014 | name in title: Glybera |
| PMID 24649836 | Clinical development of gene therapy needs a tailored approach: a regulatory perspective from the European Union. | Human gene therapy. Clinical development | 2014 | name in abstract: alipogene tiparvovec |
| PMID 24671677 | Engineering HSV-1 vectors for gene therapy. | Methods in molecular biology (Clifton, N.J.) | 2014 | name in abstract: alipogene tiparvovec |
| PMID 24845847 | Gene therapy: a promising approach to treating spinal muscular atrophy. | Human gene therapy | 2014 | name in abstract: Glybera |
| PMID 25083925 | Recent advances in pharmacotherapy for hypertriglyceridemia. | Progress in lipid research | 2014 | name in abstract: alipogene tiparvovec |
| PMID 25091489 | State-of-the-art human gene therapy: part I. Gene delivery technologies. | Discovery medicine | 2014 | name in abstract: Glybera |
| PMID 25393537 | Intramuscular injection of AAV8 in mice and macaques is associated with substantial hepatic targeting and transgene expression. | PloS one | 2014 | name in abstract: Glybera |
| PMID 25459120 | Gene therapy of the central nervous system: general considerations on viral vectors for gene transfer into the brain. | Revue neurologique | 2014 | name in abstract: Glybera |
| PMID 25468918 | Dyslipidaemia: what's around the corner? | Clinical medicine (London, England) | 2014 | name in abstract: alipogene tiparvovec |
| PMID 23126631 | Alipogene tiparvovec: gene therapy for lipoprotein lipase deficiency. | Expert opinion on biological therapy | 2013 | name in title: alipogene tiparvovec |
| PMID 23527320 | Alipogene tiparvovec for the treatment of lipoprotein lipase deficiency. | Drugs of today (Barcelona, Spain : 1998) | 2013 | name in title: alipogene tiparvovec |
| PMID 23566848 | Gene therapy on demand: site specific regulation of gene therapy. | Gene | 2013 | name in abstract: Glybera |
| PMID 23618815 | History of gene therapy. | Gene | 2013 | name in abstract: Glybera |
| PMID 23808604 | Lessons learned from the clinical development and market authorization of Glybera. | Human gene therapy. Clinical development | 2013 | name in title: Glybera |
| PMID 23954897 | Regulatory evaluation of Glybera in Europe - two committees, one mission. | Nature reviews. Drug discovery | 2013 | name in title: Glybera |
| PMID 22340447 | New lipid-lowering drugs: an update. | International journal of clinical practice | 2012 | name in abstract: alipogene tiparvovec |
| PMID 22679644 | Glybera and the future of gene therapy in the European Union. | Nature reviews. Drug discovery | 2012 | name in title: Glybera |
| PMID 22691709 | Gene therapy for lipoprotein lipase deficiency. | Current opinion in lipidology | 2012 | name in abstract: alipogene tiparvovec |
| PMID 23023051 | Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union. | Molecular therapy : the journal of the American Society of Gene Therapy | 2012 | name in title: Glybera |
| PMID 20427244 | Review of the clinical development of alipogene tiparvovec gene therapy for lipoprotein lipase deficiency. | Atherosclerosis. Supplements | 2010 | name in title: alipogene tiparvovec |
| PMID 19455266 | Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology | 2009 | name in abstract: alipogene tiparvovec |
| PMID 20072945 | Alipogene tiparvovec, an adeno-associated virus encoding the Ser(447)X variant of the human lipoprotein lipase gene for the treatment of patients with lipoprotein lipase deficiency. | Current opinion in molecular therapeutics | 2009 | name in title: alipogene tiparvovec |
NIH grants
| Project | Title | Organisation | PI | Years | Linked by |
|---|---|---|---|---|---|
| R01EB034573 | Engineering the biology of AAV secretion and production | DUKE UNIVERSITY | ASOKAN, ARAVIND | 2023–2026 | name in abstract: Glybera |
Notes
First gene therapy authorised in the EU (Glybera, 2012), for familial lipoprotein lipase deficiency. The authorisation expired on 28 October 2017 after uniQure chose not to apply for renewal, citing lack of demand; recorded as withdrawn, the nearest status the spec offers.
How to cite
alipogene tiparvovec (AXP000248.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000248.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.